Validation of two clinical scores for transthyretin amyloid cardiomyopathy in a mediterranean cohort of patients at risk

Back

HFA Premium Access

Validation of two clinical scores for transthyretin amyloid cardiomyopathy in a mediterranean cohort of patients at risk

Session: Myocardial disease - clinical 3

Topic: Clinical

Speaker: Doctor M. Llevadot Sesmilo (Badalona, ES)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Mireia Llevadot Sesmilo

Germans Trias and Pujol Hospital, Badalona (Spain)

1 presentation

0 follower

7 more presentations in this session

Temporal trends and clinical characteristics of variant versus wild-type transthyretin amyloid cardiomyopathy in Asian population: the Korean nationwide cohort study

Speaker: Professor J. Youn (Seoul, KR)

Impact of the non-invasive diagnostic algorithm on clinical presentation and prognosis in a nationwide multicentric light-chain and transthyretin-related cardiac amyloidosis cohort

Speaker: Doctor G. Tini Melato (Rome, IT)

Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study

Speaker: Doctor P. Van Der Meer (Groningen, NL)

Multimodality imaging to improve detection and prognostication of right ventricular involvement in cardiac sarcoidosis

Speaker: Doctor J. Okafor (London, GB)

Improved health-related quality of life in acoramidis-treated patients with ATTR-CM, demonstrated by improvements in KCCQ scores

Speaker: Professor M. Fontana (London, GB)

Access the full session

Myocardial disease - clinical 3

Speakers: Doctor M. Llevadot Sesmilo, Professor J. Youn, Doctor G. Tini Melato, Doctor P. Van Der Meer, Doctor J. Okafor...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources